| ²é¿´: 460 | »Ø¸´: 1 | ||
Icey±ù±ùгæ (³õÈëÎÄ̳)
|
[ÇóÖú]
¹ØÓÚ²¡¶¾ÀàÖÆ¼Á¶³´æµÄÖÆ±¸·½·¨
|
|
¸ÕÈëÐеÄС°×£¬×öÂý²¡¶¾µÄ£¬Ïë¿ìËÙÁ˽âÂý²¡¶¾£¬DNAÒßÃ磬¼õ¶¾£¨²¡¶¾ÀࣩÒßÃçµÄ¶³´æ·½°¸£¬ÎÄÏ×»òÕßרÀû¶¼¿ÉÒÔ£¬Ð»Ð»¸÷λ´óÉñ°ï棬СŮÍò·Ö¸Ðл @Ò©µÀÈË @Ò©µÀÈË ·¢×ÔСľ³æIOS¿Í»§¶Ë |
» ²ÂÄãϲ»¶
¹ãÎ÷Ò½¿Æ´óѧ»ù´¡Ò½Ñ§Ôº×ÔÉíÃâÒß²¡¿ÎÌâ×éÕÐÊÕ»ù´¡Ò½Ñ§Ïà¹Ø×¨ÒµµÄµ÷¼ÁÑо¿Éú
ÒѾÓÐ2È˻ظ´
°ÄÃÅÀí¹¤´óѧÈ˹¤ÖÇÄÜÒ©Îï·¢ÏÖÖÐÐÄÕÐÊÕ2026¼¶²©Ê¿Ñо¿Éú£¨ÉêÇë-¿¼ºËÖÆ£©
ÒѾÓÐ10È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ281È˻ظ´
ÖйúÒ½Ò©ÐÐÒµ·¢Õ¹ÏÖ×´£º±ê×¼Æ·ÍÆ¶¯Ò©Æ·¼ì²âˮƽÌáÉý
ÒѾÓÐ1È˻ظ´
±ê׼ƷµÄ´¿¶È¶ÔÓÚÒ©Æ·ÖÊÁ¿µÄÓ°ÏìÓжà´ó£¿
ÒѾÓÐ0È˻ظ´
ÈçºÎÖÆ±¸·ûºÏ¼¼ÊõÒªÇóµÄÒ©Æ·±ê׼Ʒ£¿
ÒѾÓÐ0È˻ظ´
¶ÔÕÕÆ·ÔÚÒ©Æ·Ñз¢ÖеIJ»¿É»òȱÐÔ
ÒѾÓÐ0È˻ظ´
±ê׼ƷµÄ·ÖÀàºÍÓÃ;£¬ÄãÖªµÀ¶àÉÙ£¿
ÒѾÓÐ0È˻ظ´
ÔÓÖʶÔÕÕÆ·¼Û¸ñÈçºÎ½ç¶¨ºÍÕýȷʹÓ÷½·¨
ÒѾÓÐ0È˻ظ´
ÔÑÐÖÆ¼Á¡¢·ÂÖÆÒ©£ºÔÓÖʶÔÕÕÆ·ÔÚÒ©Æ·Éú²úÖеÄÓ¦ÓÃ
ÒѾÓÐ0È˻ظ´
zhttt333
гæ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 60.5
- Ìû×Ó: 18
- ÔÚÏß: 8.6Сʱ
- ³æºÅ: 19956877
- ×¢²á: 2019-11-29
- ÐÔ±ð: GG
- רҵ: ²¡¶¾¡¢²¡¶¾¸ÐȾÓëËÞÖ÷ÃâÒß
|
Reference and Patent samples: vaccination against foot-and-mouth disease virus: strategies and effectiveness 2009, patent;tabilizers for freeze-dried vaccines, 2011,patent; Preservation of the Immunogenicity of Dry-powder Influenza H5N1 Whole Inactivated Virus Vaccine at Elevated Storage Temperatures, AAPS J. 2010 Jun; 12(2): 215¨C222. |
2Â¥2019-12-30 10:40:09














»Ø¸´´ËÂ¥
120